10-K: Catheter Precision's 2024 10-K Filing Reveals Ongoing Losses and Need for Capital

Catheter Precision's 2024 10-K filing highlights continued losses, a need for additional capital, and ongoing efforts to commercialize its VIVO and LockeT products.

Summary

• Catheter Precision's 10-K filing for 2024 reveals a history of losses and the expectation of incurring additional losses.
• The company needs to raise additional funds to finance operations and continue as a going concern.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's accumulated deficit was approximately $292 million at December 31, 2024.
• The company had approximately $2.9 million in cash and cash equivalents as of December 31, 2024.
• Net cash used in operating activities was approximately $9.3 million for the year ended December 31, 2024.
• The company is focused on commercializing its VIVO and LockeT products.
• The company hired a new Chief Commercial Officer, two regional directors, eight territory managers and four clinical support specialists during 2024.
• The company is developing a generation 3 of VIVO with expanded indications.
• The company acquired PeriKard, LLC in January 2025 to expand its product portfolio.
• The company identified material weaknesses in its internal control over financial reporting.
• The company is implementing a plan to remediate the material weaknesses.
• The company is subject to pervasive and continuing regulation by the FDA and other regulatory agencies.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with ongoing losses and a need for additional capital. While there are some positive developments, the overall tone is negative due to the company's financial instability.

Positives

• The company is focused on commercializing its VIVO and LockeT products.
• The company is developing a generation 3 of VIVO with expanded indications.
• The company acquired PeriKard, LLC in January 2025 to expand its product portfolio.
• The company is implementing a plan to remediate the material weaknesses in internal control over financial reporting.

Negatives

• The company has a history of losses and expects to incur additional losses.
• The company needs to raise additional funds to finance operations and continue as a going concern.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company identified material weaknesses in its internal control over financial reporting.

Risks

• The company may not be able to raise additional funds when necessary, or the terms of any financings may not be advantageous.
• The company may never achieve profitability.
• The company's material weaknesses in internal control over financial reporting could adversely affect its ability to report its results of operations and financial condition accurately and in a timely manner.
• The company may be unable to compete successfully with companies in its highly competitive industry.
• The company's revenues may depend on its customers receipt of adequate reimbursement from private insurers and government sponsored healthcare programs.
• The company is subject to pervasive and continuing regulation by the FDA and other regulatory agencies.

Future Outlook

The company expects operating losses and negative cash flows to continue for the foreseeable future as it invests in its commercial capabilities. The company believes that its current cash on hand will not be sufficient to fund its current operations, and expects the need to complete an additional financing sometime in the next three to six months.

Industry Context

The electrophysiology market is rapidly growing, driven by population growth, increasing rates of heart disease, and the rising cost of healthcare. The catheter ablation market, in particular, is expected to grow significantly in the coming years.

Comparison to Industry Standards

• The catheter ablation market was $3.5 billion in 2022 and is estimated by Global Market Insights to grow to $14.5 billion in 2032.
• The ventricular ablation market is estimated by Global Market Insights to grow at a rate of 14.5% CAGR through 2032.
• Competitors in the cardiac electrophysiology space include Medtronic, Plc., Abbott Laboratories, Biosense-Webster (J&J) and Boston Scientific Corp.
• LockeT's direct competitors include Abbotts Perclose device, Haemonetics VASCADE device and Inari Medicals FlowStasis device.

Related Party Transactions

• The company issued $1.5 million of related party notes payable in Q2 and Q3 2024 that will become due and payable on January 31, 2026.
• The company is obligated to pay royalties under various royalty agreements to related parties.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by cost-cutting measures or changes in operations.
• Customers may be impacted by the company's ability to continue providing its products and services.
• Suppliers and creditors may be affected by the company's financial instability.

Next Steps

• The company plans to remediate the material weaknesses in internal control over financial reporting.
• The company plans to collect data via the Coventry study to support a new 510(k) submission to expand the indications for use of the current VIVO product with the FDA to include ischemic hearts.
• The company plans to submit the EU registry data for publication submission in early Q2 2025.
• The company plans to begin enrollment for Phase IV LockeT clinical study by April 2025 and take 6 months to complete.
• The company plans to submit Phase V LockeT clinical study to IRB in February 2025.

Key Dates

Keywords

Catheter Precision, VIVO System, LockeT, financial results, going concern, capital raise, electrophysiology, medical devices, 10-K filing